Home » GSK Sells Rights to Old IBS Drug Lotronex to Prometheus
GSK Sells Rights to Old IBS Drug Lotronex to Prometheus
GlaxoSmithKline has sold off the U.S. rights to its irritable bowel syndrome drug Lotronex to Prometheus Laboratories, which will continue to distribute the treatment through a restricted use programme across the Atlantic.
PharmaTimes
Upcoming Events
-
07May
-
14May
-
30May